Heather Tillman

Heather Tillman

Auto-generated profile, based on publicly available information

Heather Tillman

Department of Pathology, St. Jude Children’s Research Hospital, Memphis, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2021 in Nature
Verified
Journal Article
Closed access
PDF file
GNGregory A. Newby
Gregory A. Newby
JYJonathan S. Yen
Jonathan S. Yen
KWKaitly J. Woodard
Kaitly J. Woodard
TMThiyagaraj Mayuranathan
Thiyagaraj Mayuranathan
CLCicera R. Lazzarotto
Cicera R. Lazzarotto
DLDavid R. Liu
David R. Liu

23 May 2018 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
AKApurva Kanneganti
Apurva Kanneganti
MKMalireddi R. K.Subbarao
Malireddi R. K.Subbarao
PSPedro Saavedra
Pedro Saavedra
LWLieselotte Vande Walle
Lieselotte Vande Walle
HGHanne Van Gorp
Hanne Van Gorp
MLMohamed Lamkanfi
Mohamed Lamkanfi
Pyroptosis is an inflammasome-induced lytic cell death mode, the physiological role of which in chronic inflammatory diseases is unknown. Familial Mediterranean Fever (FMF) is the most common monogenic autoinflammatory disease worldwide, affecting an estimated 150,000 patients. The disease is caused by missense mutations in Mefv that activate the Pyrin inflammasome, but the pathophysiologic mechanisms driving autoinflammation in FMF are incompletely understood. Here, we show that Clostridium difficile infection of FMF knock-in macrophages that express a chimeric FMF-associated MefvV726A Pyrin elicited pyroptosis and gasdermin D (GSDMD)–mediated interleukin (IL)-1β secretion. Importantly, in vivo GSDMD deletion abolished spontaneous autoinflammatory disease. GSDMD-deficient FMF knock-in mice were fully protected from the runted growth, anemia, systemic inflammatory cytokine production, neutrophilia, and tissue damage that characterize this autoinflammatory disease model. Overall, this work identifies pyroptosis as a critical mechanism of IL-1β–dependent autoinflammation in FMF and highlights GSDMD inhibition as a potential antiinflammatory strategy in inflammasome-driven diseases.

1 April 2018 in Cell Reports
Verified
Journal Article
Open access
YWYvona Ward
Yvona Ward
RLRoss Lake
Ross Lake
FFFarhoud Faraji
Farhoud Faraji
JSJamie Sperger
Jamie Sperger
PMPhilip Martin
Philip Martin
KKKathleen Kelly
Kathleen Kelly
Tumor cells initiate platelet activation leading to the secretion of bioactive molecules, which promote metastasis. Platelet receptors on tumors have not been well-characterized, resulting in a critical gap in knowledge concerning platelet-promoted metastasis. We identify a direct interaction between platelets and tumor CD97 that stimulates rapid bidirectional signaling. CD97, an adhesion G protein-coupled receptor (GPCR), is an overexpressed tumor antigen in several cancer types. Purified CD97 extracellular domain or tumor cell-associated CD97 stimulated platelet activation. CD97-initiated platelet activation led to granule secretion, including the release of ATP, a mediator of endothelial junction disruption. Lysophosphatidic acid (LPA) derived from platelets induced tumor invasiveness via proximal CD97-LPAR heterodimer signaling, coupling coincident tumor cell migration and vascular permeability to promote transendothelial migration. Consistent with this, CD97 was necessary for tumor cell-induced vascular permeability in vivo and metastasis formation in preclinical models. These findings support targeted blockade of tumor CD97 as an approach to ameliorate metastatic spread.

11 July 2019 in Blood
Verified
Journal Article
Open access
PDF file
SASabrin Albeituni
Sabrin Albeituni
KVKatherine C. Verbist
Katherine C. Verbist
PTPaige E. Tedrick
Paige E. Tedrick
HTHeather Tillman
Heather Tillman
JPJennifer Picarsic
Jennifer Picarsic
KNKim E. Nicols
Kim E. Nicols
Hemophagocytic lymphohistiocytosis (HLH) is an often-fatal disorder characterized by the overactivation of T cells and macrophages that excessively produce proinflammatory cytokines, including interferon-γ (IFN-γ). Previously, we reported that the JAK inhibitor ruxolitinib dampens T-cell activation and lessens inflammation in a model of HLH in which perforin-deficient (Prf1−/−) mice are infected with lymphocytic choriomeningitis virus (LCMV). Ruxolitinib inhibits signaling downstream of IFN-γ, as well as several other JAK-dependent cytokines. As a consequence, it remained unclear whether ruxolitinib was exerting its beneficial effects in HLH by inhibiting IFN-γ signaling or by targeting signaling initiated by other proinflammatory cytokines. To address this question, we compared the effects of ruxolitinib with those obtained using an IFN-γ–neutralizing antibody (αIFN-γ) in 2 murine HLH models. In both models, ruxolitinib and αIFN-γ reduced inflammation-associated anemia, indicating that ruxolitinib operates in an IFN-γ–dependent manner to reverse this HLH manifestation. In contrast, the number and activation status of T cells and neutrophils, as well as their infiltration into tissues, were significantly reduced following treatment with ruxolitinib, but they remained unchanged or were increased following treatment with αIFN-γ. Notably, despite discontinuation of ruxolitinib, LCMV-infected Prf1−/− mice exhibited enhanced survival compared with mice in which αIFN-γ was discontinued. This protective effect could be mimicked by transient treatment with αIFN-γ and a neutrophil-depleting antibody. Thus, ruxolitinib operates through IFN-γ–dependent and -independent mechanisms to dampen HLH by targeting the deleterious effects of T cells and neutrophils, with the latter representing an unappreciated and understudied cell type that contributes to HLH pathogenesis.

9 August 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
IAIda Annunziata
Ida Annunziata
DVDiantha van de Vlekkert
Diantha van de Vlekkert
Elmar WolfElmar Wolf
Elmar Wolf
DFDavid Finkelstein
David Finkelstein
GNGeoffrey Neale
Geoffrey Neale
Alessandra D'azzoAlessandra D'azzo
Alessandra D'azzo
Coordinated regulation of the lysosomal and autophagic systems ensures basal catabolism and normal cell physiology, and failure of either system causes disease. Here we describe an epigenetic rheostat orchestrated by c-MYC and histone deacetylases that inhibits lysosomal and autophagic biogenesis by concomitantly repressing the expression of the transcription factors MiT/TFE and FOXH1, and that of lysosomal and autophagy genes. Inhibition of histone deacetylases abates c-MYC binding to the promoters of lysosomal and autophagy genes, granting promoter occupancy to the MiT/TFE members, TFEB and TFE3, and/or the autophagy regulator FOXH1. In pluripotent stem cells and cancer, suppression of lysosomal and autophagic function is directly downstream of c-MYC overexpression and may represent a hallmark of malignant transformation. We propose that, by determining the fate of these catabolic systems, this hierarchical switch regulates the adaptive response of cells to pathological and physiological cues that could be exploited therapeutically.

1 August 2015 in Cancer Research
Verified
Journal Article
Closed access
PDF file
YCYung-Sheng Chang
Yung-Sheng Chang
WCWei-Yu Chen
Wei-Yu Chen
JYJuan Juan Yin
Juan Juan Yin
HSHeather Sheppard-Tillman
Heather Sheppard-Tillman
JHJiaoti Huang
Jiaoti Huang
YLYen-Nien Liu
Yen-Nien Liu
Dysregulation of the EGFR signaling axis enhances bone metastases in many solid cancers. However, the relevant downstream effector signals in this axis are unclear. miR-1 was recently shown to function as a tumor suppressor in prostate cancer cells, where its expression correlated with reduced metastatic potential. In this study, we demonstrated a role for EGFR translocation in regulating transcription of miR-1-1, which directly targets expression of TWIST1. Consistent with these findings, we observed decreased miR-1 levels that correlated with enhanced expression of activated EGFR and TWIST1 in a cohort of human prostate cancer specimens and additional datasets. Our findings support a model in which nuclear EGFR acts as a transcriptional repressor to constrain the tumor-suppressive role of miR-1 and sustain oncogenic activation of TWIST1, thereby leading to accelerated bone metastasis. Cancer Res; 75(15); 3077–86. ©2015 AACR.